title: ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease.
authors.affiliation: Molecular Profiling and Research Informatics, Merck Research Laboratories, West Point, PA 19486, USA. david_stone4@merck.com
authors.forename: D J
authors.initials: DJ
authors.lastname: Stone
authors.forename: C
authors.initials: C
authors.lastname: Molony
authors.forename: C
authors.initials: C
authors.lastname: Suver
authors.forename: E E
authors.initials: EE
authors.lastname: Schadt
authors.forename: W Z
authors.initials: WZ
authors.lastname: Potter
mesh_terms: D000369:Aged, 80 and over; D000483:Alleles; D000544:Alzheimer Disease / Q000188:drug therapy / Q000235:genetics*; D001057:Apolipoproteins E / Q000235:genetics*; D015415:Biomarkers / Q000032:analysis*; D017322:Clinical Trials, Phase II as Topic / Q000379:methods; D003071:Cognition / Q000502:physiology; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D001057:Apolipoproteins E; D015415:Biomarkers